Kornimate/medical-research-clean huggingface dataset:
kinesiological taping in individuals with meniscus injury

Conditions: Meniscus Tears

Summary: this study aims to explore how kinesiology taping affects people with mild to moderate meniscus injuries (grades i/ii), focusing on pain, movement fears, muscle strength, balance, joint movement, and quality of life. two groups will be involved: one will receive kinesiology taping on the thigh muscle with some tension, while the other will receive a placebo tape with no tension. researchers will measure various factors, including pain and muscle strength, both before and 48-72 hours after taping.

this study aims to understand the short-term (acute) effects of kinesiology taping on people with mild to moderate meniscus injuries (grade i/ii). these injuries, affecting the cartilage in the knee, can cause pain, reduced mobility, and fear of movement. kinesiology taping, a popular therapy, involves applying elastic tape to support muscles and joints. this research looked at whether taping could improve pain, muscle strength, movement, balance, and quality of life in patients with these knee injuries. study design the study will use a randomized, placebo-controlled, and double-blinded design, meaning that patients were randomly assigned to two groups, and neither the patients nor the researchers knew which group each person was in during the treatment. experimental group: will receive kinesiology taping on the quadriceps muscle (the large muscle at the front of the thigh) using a 'y-shaped' technique with moderate tension (25-50% stretch). control group: will receive a placebo tape applied without tension and placed in a different direction. measurements to evaluate the effects of taping, several aspects will be measured both before the tape was applied and 48-72 hours later: pain levels fear of movement (kinesiophobia) muscle strength (ability to extend the knee) proprioception (awareness of limb position and force applied) joint range of motion (how much the knee can bend and straighten) joint position sense (accuracy in detecting knee position with eyes closed) quality of life, using a questionnaire (sf-36) that assesses various aspects like physical function and energy levels.

Eligibility criteria:
inclusion criteria: * patients diagnosed with meniscus grade i/ii, * who agreed to participate in the study * signed the voluntary consent form exclusion criteria: * pregnant individuals * individuals with additional knee injuries (e.g., ligament tears) or chronic conditions affecting the knee (e.g., arthritis). * patients with grade iii meniscus tears or more severe injuries. * who had knee surgery in the last 6 months. * patients with skin conditions or allergies to adhesive materials or kinesiology tape. * individuals with neurological conditions such as multiple sclerosis

Keywords: kinesiology taping pain quality of life meniscus injury
a study of the metabolic syndrome in patients with systemic lupus erythematosus

Conditions: Metabolic Syndrome; Cardiovascular Risk Factors; Systemic Lupus Erythematosus

Summary: an increased prevalence of the metabolic syndrome has been found in patients with systemic lupus erythematosus in recent years.

this study will investigate the prevalence of the metabolic syndrome in patients with sle in taiwan. we expect our study will provide further understanding of the association between sle and metabolic syndrome, which may give direction to prevent late cardiovascular morbidity and mortality in sle patients.

Eligibility criteria:
inclusion criteria: * persons aged 18 and above. * persons fulfill the diagnostic criteria of the 1997 american college of rheumatology for systemic lupus erythematosus in the patient group. exclusion criteria: * exclude a history myocardial infarction, angina or stroke.

Keywords: metabolic syndrome systemic lupus erythematosus
data analysis for drug repurposing for effective alzheimer's medicines (dream)- pentoxifylline versus cilostazol

Conditions: Peripheral Artery Disease

Summary: this study aims to evaluate the comparative risk of dementia/alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

this is a non-randomized, non-interventional study that is part of the dream study of brigham and women's hospital. dream is led by dr. madhav thambisetty, md, phd, chief of the clinical and translational neuroscience section, laboratory of behavioral neuroscience, national institute on aging (nia) intramural research program. this study aims to evaluate the comparative risk of dementia/alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.

Eligibility criteria:
please see https://docs.google.com/spreadsheets/d/17qj294pffmocfyleq0esvn7hlj6mob-0djcr1rl3kfk/edit?usp=sharing or appendix a (https://drive.google.com/drive/folders/1-lr6dr_ap44goryjcad_nwrhjppsikdu?usp=sharing) for full code and algorithm definitions. medicare timeframe: 2008 to 2018 (end of data availability) inclusion criteria: * 1. aged \>/= 65 years on the index date * 2. enrollment in medicare part a, b, and d with no hmo coverage for 365 days prior to and including cohort entry date * 3. at least two claims with peripheral artery disease diagnosis measured 365 days prior to drug initiation exclusion criteria: * 1. prior history of dementia measured anytime prior to cohort entry date * 2. prior history of nursing home admission in the 365 days prior to the cohort entry date * 3. prior history of pentoxifylline or cilostazol use anytime prior to cohort entry date
a bioavailability study of rifabutin and lopinavir/ritonavir in healthy adult subjects

Conditions: HIV; Tuberculosis

Summary: the purpose of this study is to study the safety, tolerability and pharmacokinetics of rifabutin dosing with lopinavir/ritonavir tablets in healthy volunteers.


Eligibility criteria:
inclusion criteria: * adult male or female 18-55 yrs. * subject has provided written consent. * subject is in general good health. * if female, subject is postmenopausal. * if female, subject is not pregnant and is not breast-feeding. * subject must use birth control methods or be surgically sterile. exclusion criteria: * subject is hav-igm, hbsag or hiv ab positive. * positive screen for drugs of abuse, alcohol, or smoking. * cannot be on any medication, including over the counter drugs. * cannot have previous history of alcohol or drug abuse. * cannot have history of any major diseases or disorders.

Keywords: hiv co-infected with tuberculosis
a randomized,open,controlled clinical study to evaluate the efficacy of asc09f and ritonavir for 2019-ncov pneumonia

Conditions: 2019-nCoV Pneumonia

Summary: based on oseltamivir treatment, evaluate the efficacy and safety of asc09/ritonavir compound tablets(asc09f) or ritonavir tablets for 2019-ncov infection patients.


Eligibility criteria:
inclusion criteria: 1. age:18\~55 years old, unlimited gender. 2. laboratory (rt-pcr) confirmed infection with 2019-ncov and accompanied with clinical manifestations. 3. patients with newly diagnosed respiratory discomfort who have been hospitalized (the proper diagnosis time is less than 7 days). 4. women who have no planned pregnancy in the next six months,and are willing to take effective measures to prevent contraception from the first dose of study drug to 30 days after the last dose. 5. agree not to participate in other clinical studies within 30 days from the first dose of the study drug to the last dose. 6. patients who voluntarily sign informed consent forms. exclusion criteria: 1.2019-ncov severe pneumonia patients. meet the definition of severe pneumonia(comply with any of the followings): 1. respiratory distress ,rr≥30 bpm; 2. in a resting state:spo2≤93%; 3. pao2/ fio2≤300mmhg. 2.2019-ncov critical and severe pneumonia patients.comply with any of the followings:respiratory failure and need mechanical ventilation;shock;patients combined with other organ failure need icu monitoring and treatment. 3.severe liver disease(such as:the childpugh score≥c;ast \> 5 times the upper limit). 4.patients who are allergic to the ingredients of asc09/ritonavir compound tablets. 5.patients with definite contraindications in ritonavir tablets. 6.female subjects were positive for the pregnancy test during the screening period. 7.researcher judges unsuitable for participation in this clinical trial(such as:during the study patients may be transferred to hospital for treatment;patients with multiple underlying diseases, etc)
pain management in laparoscopic living-donor nephrectomy: the impact of erector spinae plane block (espb) on perioperative period

Conditions: Pain, Postoperative; Donor Site Complication

Summary: laparoscopic living donor nephrectomy (lldn) is a safe procedure and rapid wound healing, affecting the quality of life. the physiology of postoperative pain after lldn has been attributed to reasons such as tissue damage, residual pneumoperitoneum, and diaphragm irritation. in terms of patient comfort after lldn, pain control is provided by iv analgesics, local anesthetic injection instead of incision, and regional techniques. regional anesthesia techniques for postoperative pain control have become popular in recent years. today, many blocks are performed with ultrasonography (usg) to reduce the severity of pain after laparoscopic and open surgeries. in 2016, forero et al. erector spinae plane block (espb) had been defined and used successfully in thoracic and abdominal surgeries. in our clinic, peripheral nerve blocks such as intravenous patient-controlled analgesia (pca) and espb are applied for postoperative analgesia. the method of analgesia is suitable for the surgery and explained to the patients. this study; in lldn operations, it was aimed to compare the bilateral esp block performed with usg in terms of postoperative pain scores and opioid analgesic consumption compared to patients without any block. before the operation, the anesthesiologist in charge of the anesthesia outpatient clinic provides information about both anesthesia and postoperative pain management methods suitable for surgery. this is the standard practice in our clinic. before anesthesia, anesthesia and analgesia methods will be briefly reminded to the patient who has come for the operation. he/she will be asked if he/she wants to apply postoperative analgesia. block procedure will be applied to patients who want esp block. standard analgesia will be applied to all patients. regardless of the study, patients who underwent lldn operation will be interviewed in the postoperative period with or without an esp block for postoperative analgesia. the data and postoperative evaluations of the patients who agreed to participate in the study will be recorded for study purposes. the patient data will be taken from the hospital registration system.


Eligibility criteria:
inclusion criteria: * all patients aged 18-75 who were operated on under general anesthesia for lldn surgery and agreed to participate in the study will be included. exclusion criteria: * participants who did not accept the study, had intraoperative complications, and whose laparoscopic operation was canceled will not be included in the study.

Keywords: pain management laparoscopic living-donor nephrectomy erector spinae plane block
impact of low dose unfractionated heparin treatment on inflammation in sepsis

Conditions: Severe Sepsis With Septic Shock; Severe Sepsis Without Septic Shock

Summary: sepsis is a clinical syndrome which infection trigger systemic inflammatory response. uncontrolled inflammatory process leads to multiple organ dysfunction and cause early mortality in severe sepsis. unfractionated heparin is an anticoagulant that widely used either for dvt prophylaxis or treatment of disseminated intravascular coagulation. heparin also have an anti-inflammatory effect through downregulates nuclear factor kappa b and tumor necrosis factor alpha. aim of this study is to determine effects of low dose unfractionated heparin treatment on inflammation in severe sepsis patient.


Eligibility criteria:
inclusion criteria: * patients with severe sepsis and septic shock define by revised sepsis criteria (2001) * within 48 hour diagnose sepsis * agree to participate exclusion criteria: * pregnancy and lactation * severe thrombocytopenia, platelet less than 30.000/mm3 * bleeding or high risk of major bleeding * during anticoagulant treatment * after thrombolytic treatment * decompensated chronic liver diseases * chronic kidney diseases on dialysis treatment * during high dose corticosteroid treatment * hiv with cd4 count below 50/mm3 * indication for high dose heparin treatment

Keywords: heparin sepsis inflammation
safety and efficacy study of catioprost® (unpreserved latanoprost 0.005% emulsion) compared to travatan z® to treat glaucoma and ocular surface disease

Conditions: Glaucoma; Ocular Hypertension; Ocular Surface Disease

Summary: the purpose of this study is to compare: * the effect of catioprost® and travatan z® on the ocular surface disease (osd) in subjects with glaucoma or ocular hypertension and ocular surface disease. * the intraocular pressure (iop) lowering effect and safety of catioprost® and travatan z® in subjects with glaucoma or ocular hypertension and ocular surface disease.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age at visit 1 (iop screening), of either sex and any race or ethnicity. * be willing and able to provide written informed consent prior to any study procedures being performed. * be willing and able to follow all instructions and attend all study visits. * have a documented diagnosis of ocular hypertension, open angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or chronic angle closure glaucoma with a patent iridotomy requiring treatment with an ocular hypertensive therapy in the study eye. * agree to submit to a pregnancy test at visit 1 and at visit 4, or not be of childbearing potential. * agree to use an acceptable method of contraception for the duration of the study or not be of childbearing potential. acceptable methods of birth control include: spermicide with barrier, oral, transdermal, injectable, or implantable contraception, iud, abstinence, and surgical sterilization of partner. female subjects are not of childbearing potential if they have had a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or are post-menopausal by at least 12 months. exclusion criteria: * have known sensitivity or poor tolerance to latanoprost or travoprost or any other component of the study medications. * have any form of glaucoma other than open angle glaucoma (with or without a pigment dispersion or pseudoexfoliation component), ocular hypertension or chronic angle closure glaucoma with patent iridotomy in either eye. * have an iop at any time point during the screening or baseline visits (visits 1 or 2) of \> 34 mmhg in either eye. * be currently pregnant, nursing, or planning a pregnancy during the study period; or be a woman that has a positive pregnancy test. * have a history of any significant ocular condition(s) in either eye that would contraindicate the use of latanoprost or travoprost, or that might affect the study conduct or the interpretation of the study results. * have any abnormality preventing reliable goldmann applanation tonometry of either eye. * have been previously non-responsive to prostaglandin analog therapy for reduction of iop. * have prior (within 30 days of visit 1) or anticipated concurrent use of an investigational drug or device during the study period. * have a condition or a situation, which in the investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation.
dynamic hyperinflation and tiotropium

Conditions: COPD

Summary: we will detect dynamic hyperinflation (dh) in 40 copd (chronic obstructive pulmonary disease) patients with moderately severe disease using metronome paced hyperventilation (mph) with inspiratory capacity as the primary end point. hypothesis: is tiotropium capable of lung volume protecting inspiratory capacity from mph induced dh vs placebo in a randomized crossover double blinded study.

study completed with 29 patients studied. data is being analyzed to evaluate trough and peak effect of 18 µg tiotropium vs placebo on fev 1 (l)(forced expiratory capacity in one second), inspiratory capacity and functional residual volume. in addition, we will study the effect of 18 µg tiotropium vs placebo on metronome paced hyperventilation induced dynamic hyperinflation. we will also evaluate the effect of tiotropium induced increase in ic (inspiratory capacity) vs extent of emphysema as evaluated on high resolution thin section ct lung

Eligibility criteria:
inclusion criteria: * moderately severe copd patients age 40-85 yr with post 180ug albuterol fev 1 between 60 and 79% predicted and fev 1/fvc \< 70%. * smoking history \> 10 pack yr. * clinically stable x 6 weeks. * no oxygen usage. exclusion criteria: * history of asthma * clinically unstable * any other significant medical problem precluding full cooperation for study
the growth factor signature (gfs) as an intermediate biomarker of response for development of pi3k-pathway inhibitors in patients with breast cancer (mk-8669-050)

Conditions: Breast Cancer

Summary: this clinical trial will evaluate whether treatment with ridaforolimus, dalotuzumab, or ridforolimus/dalotuzumab combination therapy reduces growth factor signature (gfs) score among participants with breast cancer.


Eligibility criteria:
inclusion criteria: * participant has operable stage i-iiia invasive breast cancer of the following subtype: er-positive, her2-negative tumor with histologic grade 2 or 3 and ki67 ≥ 15% * tumor is at least 2 cm in diameter as assessed by physical or radiographic exam * participant consents to provide an existing tissue sample or to have a core needle biopsy before drug administration * participant consents to provide tissue samples following drug administration by a second core needle biopsy or from a surgical specimen * participant must have adequate organ function exclusion criteria: * participant has received any prior chemotherapy, biological therapy or radiotherapy for breast cancer * participant has a known hypersensitivity to the components of study drugs or their analogs, including hypersensitivity to macrolide antibiotics (e.g. clarithromycin, erythromycin, azithromycin). * participant has poorly controlled diabetes mellitus, or requires insulin for glucose control. * participant is unable to swallow capsules and/or absorb oral medications * participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study. * participant is known to be human immunodeficiency virus (hiv)-positive * participant has known history of active hepatitis b or c. * participant is concurrently using growth hormone (gh) or growth hormone inhibitors * participant has significant or uncontrolled cardiovascular disease, including heart failure, unstable angina, or a myocardial infarction within the last 6 months

Keywords: breast cancer ridaforolimus ridaforolimus/dalotuzumab combination therapy
effectiveness of accelerated deep tms in ocd

Conditions: Obsessive-Compulsive Disorder

Summary: h-coil high-frequency deep transcranial magnetic stimulation (dtms) over the medial prefrontal cortex (mpfc) and anterior cingulate cortex (acc) has been approved by the food and drug administration for use in treatment-resistant obsessive-compulsive disorder. at the same time, there are studies in the literature showing the effectiveness of intermittent theta burst stimulation application and the advantages of short treatment duration. however, there is no strong scientific evidence yet on the effectiveness and safety of itbs (50 hz) application with a double-cone coil in obsessive-compulsive disorder patients. the aim of this study is to evaluate the effectiveness of dtms with itbs protocol on the medial prefrontal cortex (mpfc) and anterior cingulate cortex (acc) in ocd patients.

the current study aimed to investigate the effectiveness and safety of the itbs protocol, which is applied to the mpfc and acc for 5 sessions per day with a double-cone coil in treatment-resistant ocd patients. this study evaluated (i) the effectiveness of itbs (50 hz) stimulation of the mpfc and acc with a double-cone coil and (ii) the effectiveness of administering this protocol over 2 weeks rather than six weeks as approved by the fda. participants will be randomized into two parallel groups in a double-blind manner. in one group, itbs (50 hz) dtms will be applied to mpfc and acc, and in the other group, sham tms will be applied to the same regions. the application consists of a total of 50 sessions, 5 times a day. this application will last for a total of 10 days excluding weekends.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of obsessive-compulsive disorder * not having an adequate response to treatment despite the use of an sgi selective serotonin reuptake inhibitors at a sufficient dose and duration (at least 8 weeks) before the planned add-on treatment * no dose or active substance changes have been made in the treatment regimen for at least 8 weeks * aged 18-65 years * able to read and write * not having a significant medical or neurological disease exclusion criteria: * not providing consent to participate in the study * diagnosis of a psychiatric disorder, such as psychotic disorder, bipolar disorder, major depressive disorder \[hamilton depression rating scale (hdrs) score above 17\], mental retardation, alcohol-substance use disorder, and organic mental disorder (dementia, delirium, and head trauma, etc.) * diagnosis of an important medical or neurological disease (e.g., epilepsy); * mental retardation * illiteracy * having received electroconvulsive therapy (ect) or tms within the last six months; * having any prosthesis, such as an implant and pacemaker.

Keywords: obsessive compulsive disorder intermittant teta burst transcranial magnetic stimulation accelerated tms transcranial magnetic stimulation